Mirum Pharmaceuticals, Inc.

MIRM Healthcare Biotechnology

Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

80.14 2.25 −2.73%
Market cap
$5.4B
P/E
0.0×
Fwd P/E
−6.0×
Dividend yield
—
F-score
6/9
Altman Z
4.42
Beneish M
−2.46
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
3 4 6 6

+8 more TTM periods

ROE
(702.97%) (335.82%) (8.65%) (15.81%)
ROA
(97.15%) (101.04%) (3.09%) (5.70%)
ROIC
(172.96%) (298.98%) (5.74%) (11.56%)
Return on Tangible Assets
(206.89%) (267.15%) (6.76%) (11.15%)
Average Days of Receivables
85.84 85.30 86.35 82.88
Free Cash Flow per Share
(4.32) (3.44) 1.09 0.88
Free Cash Flow
(273.74) (202.55) 54.87 44.32
Other line items

Show all line items

Columns are period end dates